Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Drug Royalty has acquired 25% of Enzon Pharmaceuticals worldwide royalty interest in Peg-Intron for $92.5 million.
Subscribe to our email newsletter
DRC will also provide a $15 million milestone payment in 2012 should certain royalty recognition levels be met. Peg-Intron (peginterferon alpha-2b), is approved for the treatment of hepatitis C and is marketed worldwide by Schering-Plough.
Speaking on behalf of DRC, Paul Kirkconnell, MD, said: “We believe that Peg- Intron is one of the most advanced medications to treat hepatitis C on the market today. With access to significant capital and a long track record in completing royalty transactions, we take pride in meeting the needs of pharmaceutical companies such as Enzon.”
Peg-Intron is a Peg-enhanced version of Schering-Plough's alpha interferon product, Intron A, which is used both as a monotherapy and in combination with Rebetol (ribavirin) capsules for the treatment of chronic hepatitis C.